The FDA ruled to keep the glucose control drug Avandia on the market, with significant restrictions. Dr. Robert A. Vigersky, the immediate past president of The Endocrine Society, offers guidance to type 2 diabetes patients in a video interview available on the Hormone Foundation Web site.
In light of the FDA decision, this educational video provides patients with next steps to consider in their diabetes management, (more…)
The FDA has greatly restricted the use of controversial Type 2 diabetes drug Avandia and European regulators have banned the drug, according to an article from DLife.
In the U.S., GlaxoSmithKline is required to develop a restricted access program. The drug has been restricted to only those patients that cannot control their blood sugar by other means and are unable to take Actos, another drug in the same class.
The controversy (more…)
If you are one of the 600,000 Americans who take Avandia, you need to see your doctor right away. That’s only a small fraction of the 24 million of us here who have diabetes, but anyone who now takes it has an important — and perhaps a life-saving — decision to make.
The U.S. Food and Drug Administration just pulled the major diabetes drug Avandia (rosiglitazone) from the U.S. market — with two exceptions. This government agency (more…)
Avandia (rosiglitazone), and all diabetes medications that contain rosiglitazone will be taken off the market within the next few months, says the European Medicines Agency (EMA) which has recommended taking it off the market. Specifically, the following brands are involved – Avandia, Avandamet and Avaglim. Yesterday, the FDA (Food and Drug Administration, USA) severely restricted rosiglitazone use and ordered GlaxoSmithKline, (more…)
GlaxoSmithKline (NYSE and LSE: GSK) confirms that following a review of Avandia® (rosiglitazone maleate) by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), each agency has announced their individual regulatory decisions and the resulting actions.
In the European Union*, the EMA has suspended the marketing authorization for all rosiglitazone-containing medicines (Avandia, Avandamet® (more…)